Treatment of primary sjögren syndrome with rituximab a randomized trial

Annals of Internal Medicine

Volumn 160, Issue 4, 2014, Pages 233-242

  Devauchelle Pensec, Valerie ^a   Mariette, Xavier ^b   Jousse Joulin, Sandrine ^a   Berthelot, Jean Marie ^c   Perdriger, Aleth ^d   Puechal, Xavier ^e   Le Guern, Veronique ^e   Sibilia, Jean ^f   Gottenberg, Jacques Eric ^f   Chiche, Laurent ^g   Hachulla, Eric ^h   Hatron, Pierre Yves ^a   Goeb, Vincent ⁱ   Hayem, Gilles ^j   Morel, Jacques ^k   Zarnitsky, Charles ^l   Dubost, Jean Jacques ^m   Pers, Jacques Olivier ^n,o   Nowak, Emmanuel ^a   Saraux, Alain ^a  

^a BREST UNIVERSITY HOSPITAL   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c HÔTEL DIEU   (France)

^d SERVICE DE RHUMATOLOGIE   (France)

^e Cochin Hospital ^*  (France)

^f UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^g HÔPITAL DE LA CONCEPTION   (France)

^h UNIV LILLE   (France)

ⁱ AMIENS UNIVERSITY HOSPITAL   (France)

^j BICHAT HOSPITAL   (France)

^k LAPEYRONIE HOSPITAL   (France)

^l Centre Hospitalier Monod   (France)

^m SERVICE DE RHUMATOLOGIE   (France)

ⁿ CHU MORVAN   (France)

^o Universite de Brest   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; SJOGREN'S SYNDROME; TREATMENT OUTCOME; YOUNG ADULT;

PLACEBO; RITUXIMAB;

ADULT; ARTICLE; ASTHMA; BREAST CANCER; BRONCHITIS; CONTROLLED STUDY; COUGHING; CYTOPENIA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DRY SKIN; DYSPNEA; FATIGUE; FEMALE; FRANCE; HEADACHE; HUMAN; HYPERGLYCEMIA; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PAIN; PARALLEL DESIGN; PRIORITY JOURNAL; PURPURA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT DISEASE; SJOEGREN SYNDROME; SKIN ALLERGY; SKIN CARCINOMA; SKIN INFECTION; SNEEZING; THROAT IRRITATION; TRACHEA DISEASE; UNIVERSITY HOSPITAL; URINARY TRACT INFECTION; VISUAL ANALOG SCALE; XEROSTOMIA;

EID: 84894243056     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Peri Y, Agmon-Levin N, Theodor E, Shoenfeld Y. Sjögren's syndrome, the old and the new. Best Pract Res Clin Rheumatol. 2012;26:105-17. [PMID: 22424197]
2. Guellec D, Cornec D, Jousse-Joulin S, Marhadour T, Marcorelles P, Pers JO, et al. Diagnostic value of labial minor salivary gland biopsy for Sjögren's syndrome: a systematic review. Autoimmun Rev. 2013;12:416-20. [PMID: 22889617]
3. Ramos-Casals M, Tzioufas AG, Stone JH, SisóA, Bosch X. Treatment of primary Sjögren syndrome: a systematic review. JAMA. 2010;304:452-60. [PMID: 20664046]
4. Le Pottier L, Devauchelle V, Fautrel A, Daridon C, Saraux A, Youinou P, et al. Ectopic germinal centers are rare in Sjogren's syndrome salivary glands and do not exclude autoreactive B cells. J Immunol. 2009;182:3540-7. [PMID: 19265132]
5. Daridon C, Pers JO, Devauchelle V, Martins-Carvalho C, Hutin P, Pennec YL, et al. Identification of transitional type II B cells in the salivary glands of patients with Sjögren's syndrome. Arthritis Rheum. 2006;54:2280-8. [PMID: 16802367]
6. Jonsson MV, Szodoray P, Jellestad S, Jonsson R, Skarstein K. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjögren's syndrome. J Clin Immunol. 2005;25:189-201. [PMID: 15981083]
7. Talal N, Sylvester RA, Daniels TE, Greenspan JS, Williams RC Jr. T and B lymphocytes in peripheral blood and tissue lesions in Sjögren's syndrome. J Clin Invest. 1974;53:180-9. [PMID: 4586872]
8. Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse-Joulin S, et al. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum. 2007;57:310-7. [PMID: 17330280]
9. Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, et al. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum. 2005;52:2740-50. [PMID: 16142737]
10. Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J, et al. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis. 2008; 67:1541-4. [PMID: 18276741]
11. Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N, et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62:960-8. [PMID: 20131246]
12. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572-81. [PMID: 15201414]
13. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99:754-8. [PMID: 11806974]
14. Kuijpers TW, Bende RJ, Baars PA, Grummels A, Derks IA, Dolman KM, et al. CD20 deficiency in humans results in impaired T cell-independent antibody responses. J Clin Invest. 2010;120:214-22. [PMID: 20038800]
15. Mekinian A, Ravaud P, Hatron PY, Larroche C, Leone J, Gombert B, et al. Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis. 2012;71: 84-7. [PMID: 21926185]
16. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al; European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554-8. [PMID: 12006334]
17. Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, et al; EULAR Sjögren's Task Force. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis. 2010;69:1103-9. [PMID: 19561361]
18. Meiners PM, Arends S, Brouwer E, Spijkervet FK, Vissink A, Bootsma H. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab. Ann Rheum Dis. 2012;71: 1297-302. [PMID: 22258489]
19. Chisholm DM, Mason DK. Labial salivary gland biopsy in Sjögren's disease. J Clin Pathol. 1968;21:656-60. [PMID: 5697370]
20. van Bijsterveld OP. Standardization of the lysozyme test for a commercially available medium. Its use for the diagnosis of the sicca syndrome. Arch Ophthalmol. 1974;91:432-4. [PMID: 4597221]
21. Pers JO, Devauchelle V, Daridon C, Bendaoud B, Le Berre R, Bordron A, et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Arthritis Rheum. 2007;56:1464-77. [PMID: 17469105]
22. Wacholder S. Binomial regression in GLIM: estimating risk ratios and risk differences. Am J Epidemiol. 1986;123:174-84. [PMID: 3509965]
23. Spiegelman D, Hertzmark E. Easy SAS calculations for risk or prevalence ratios and differences [Editorial]. Am J Epidemiol. 2005;162:199-200. [PMID: 15987728]
24. Bjerrum K, Prause JU. Primary Sjögren's syndrome: a subjective description of the disease. Clin Exp Rheumatol. 1990;8:283-8. [PMID: 2379343]
25. Devauchelle-Pensec V, Cagnard N, Pers JO, Youinou P, Saraux A, Chiocchia G. Gene expression profile in the salivary glands of primary Sjögren's syndrome patients before and after treatment with rituximab. Arthritis Rheum. 2010;62:2262-71. [PMID: 20506202]
26. Gottenberg JE, Cagnard N, Lucchesi C, Letourneur F, Mistou S, Lazure T, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. Proc Natl Acad Sci U S A. 2006; 103:2770-5. [PMID: 16477017]
27. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al; LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64:1215-26. [PMID: 22231479]
28. Ray A, Basu S, Williams CB, Salzman NH, Dittel BN. A novel IL-10-independent regulatory role for B cells in suppressing autoimmunity by maintenance of regulatory T cells via GITR ligand. J Immunol. 2012;188:3188-98. [PMID: 22368274]
29. Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, et al. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum. 2004;50:1270-6. [PMID: 15077311]
30. Sankar V, Brennan MT, Kok MR, Leakan RA, Smith JA, Manny J, et al. Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum. 2004;50:2240-5. [PMID: 15248223]
31. Steinfeld SD, Demols P, Salmon I, Kiss R, Appelboom T. Infliximab in patients with primary Sjögren's syndrome: a pilot study. Arthritis Rheum. 2001; 44:2371-5. [PMID: 11665979]